316 related articles for article (PubMed ID: 31529722)
41. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis.
Yamada K; Mizukoshi E; Sunagozaka H; Arai K; Yamashita T; Takeshita Y; Misu H; Takamura T; Kitamura S; Zen Y; Nakanuma Y; Honda M; Kaneko S
Liver Int; 2015 Feb; 35(2):582-90. PubMed ID: 25219574
[TBL] [Abstract][Full Text] [Related]
42. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
44. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.
Wilson CG; Tran JL; Erion DM; Vera NB; Febbraio M; Weiss EJ
Endocrinology; 2016 Feb; 157(2):570-85. PubMed ID: 26650570
[TBL] [Abstract][Full Text] [Related]
45. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
46. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
Fu D; Cui H; Zhang Y
Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
[TBL] [Abstract][Full Text] [Related]
47. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance.
Matsuzaka T; Shimano H; Yahagi N; Kato T; Atsumi A; Yamamoto T; Inoue N; Ishikawa M; Okada S; Ishigaki N; Iwasaki H; Iwasaki Y; Karasawa T; Kumadaki S; Matsui T; Sekiya M; Ohashi K; Hasty AH; Nakagawa Y; Takahashi A; Suzuki H; Yatoh S; Sone H; Toyoshima H; Osuga J; Yamada N
Nat Med; 2007 Oct; 13(10):1193-202. PubMed ID: 17906635
[TBL] [Abstract][Full Text] [Related]
48. Impact of glycosylphosphatidylinositol-specific phospholipase D on hepatic diacylglycerol accumulation, steatosis, and insulin resistance in diet-induced obesity.
Masuda S; Fujishima Y; Maeda N; Tsugawa-Shimizu Y; Nakamura Y; Tanaka Y; Obata Y; Fukuda S; Nagao H; Kita S; Nishizawa H; Shimomura I
Am J Physiol Endocrinol Metab; 2019 Feb; 316(2):E239-E250. PubMed ID: 30457913
[TBL] [Abstract][Full Text] [Related]
49. Saturated and monounsaturated fatty acids in membranes are determined by the gene expression of their metabolizing enzymes SCD1 and ELOVL6 regulated by the intake of dietary fat.
Weiss-Hersh K; Garcia AL; Marosvölgyi T; Szklenár M; Decsi T; Rühl R
Eur J Nutr; 2020 Sep; 59(6):2759-2769. PubMed ID: 31676951
[TBL] [Abstract][Full Text] [Related]
50. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition.
Huang H; Lee SH; Sousa-Lima I; Kim SS; Hwang WM; Dagon Y; Yang WM; Cho S; Kang MC; Seo JA; Shibata M; Cho H; Belew GD; Bhin J; Desai BN; Ryu MJ; Shong M; Li P; Meng H; Chung BH; Hwang D; Kim MS; Park KS; Macedo MP; White M; Jones J; Kim YB
J Clin Invest; 2018 Dec; 128(12):5335-5350. PubMed ID: 30226474
[TBL] [Abstract][Full Text] [Related]
51. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
Xiao Z; Chu Y; Qin W
Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
[TBL] [Abstract][Full Text] [Related]
52. Discovery and Targeting of the Signaling Controls of
Schwartz BE; Rajagopal V; Smith C; Cohick E; Whissell G; Gamboa M; Pai R; Sigova A; Grossman I; Bumcrot D; Sasidharan K; Romeo S; Sehgal A; Pingitore P
Cells; 2020 Oct; 9(10):. PubMed ID: 33036387
[TBL] [Abstract][Full Text] [Related]
53. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
[TBL] [Abstract][Full Text] [Related]
54. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.
Turpin SM; Nicholls HT; Willmes DM; Mourier A; Brodesser S; Wunderlich CM; Mauer J; Xu E; Hammerschmidt P; Brönneke HS; Trifunovic A; LoSasso G; Wunderlich FT; Kornfeld JW; Blüher M; Krönke M; Brüning JC
Cell Metab; 2014 Oct; 20(4):678-86. PubMed ID: 25295788
[TBL] [Abstract][Full Text] [Related]
55. Bile acids induced hepatic lipid accumulation in mice by inhibiting mRNA expression of patatin-like phospholipase domain containing 3 and microsomal triglyceride transfer protein.
Hashimoto N; Han KH; Wakagi M; Ishikawa-Takano Y; Ippoushi K; Fukushima M
Nutr Res; 2021 Aug; 92():12-20. PubMed ID: 34174520
[TBL] [Abstract][Full Text] [Related]
56. FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.
Rohrbach TD; Asgharpour A; Maczis MA; Montefusco D; Cowart LA; Bedossa P; Sanyal AJ; Spiegel S
J Lipid Res; 2019 Jul; 60(7):1311-1322. PubMed ID: 31110049
[TBL] [Abstract][Full Text] [Related]
57. The Presence of Periodontitis Exacerbates Non-Alcoholic Fatty Liver Disease via Sphingolipid Metabolism-Associated Insulin Resistance and Hepatic Inflammation in Mice with Metabolic Syndrome.
Lu Z; Li Y; Chowdhury N; Yu H; Syn WK; Lopes-Virella M; Yilmaz Ö; Huang Y
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176029
[TBL] [Abstract][Full Text] [Related]
58. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
[TBL] [Abstract][Full Text] [Related]
59. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
[TBL] [Abstract][Full Text] [Related]
60. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
